Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 102

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 102
---
Market Expansion: Operating in new geographies or market segments increases reach and diversification. •Strengthened Competitive Position: A larger entity is better equipped to navigate industry competition. Financial Benefits •Operational Efficiencies: Eliminating redundancies reduces costs and potentially increases profitability. •Growth Potential: Access to new revenue opportunities and markets strengthens the financial outlook. •Resource Consolidation: The Merger creates a more robust financial foundation. Advantages to Kadimastem Officers and Directors •Increased Value for Shares Held by Insiders: Increased value for shares held by insiders due to Nasdaq liquidity and valuation advantages. •Increased Credibility: Advantages of being Nasdaq - listedcompany and potential created from enhanced status. Innovation and Collaboration •Accelerated R&D: Sharing research and resources accelerates innovation in key areas, including diabetes. •Improved Product Development: Unified efforts enhance time -to -marketefficiency. Operational Strengths •Enhanced Infrastructure: Consolidation leads to improved technological and operational frameworks. •Stronger Workforce: Combining teams increases capacity and innovation potential. Competitive Landscape •Industry Leadership: Kadimastem believes that Merger positions the combined company as a leader in its field of regenerative medicine. By harnessing the synergy of cellular therapies and novel therapeutic molecules the Merger brings innovative approaches to enhance therapeutic outcomes. •Defensive Strategy: Merging reduces vulnerabilities to external threats and competition. 12 Shareholder Value •Enhanced Returns:Improved operational efficiency and revenue generation are expected to drive shareholder value. •Long -TermGrowth:A unified strategy fosters sustainable growth opportunities. •Risk Mitigation:Diversification of products, regions, and customer bases reduces potential risks. Vision and Cultural Alignment •Unified Mission:A shared vision enhances focus on long -termgoals. •Integration Potential: Strong cultural alignment is expected to ensure successful integration post -Merger. The Kadimastem Board also considered the valuation reports and the fairness opinions prepared by Moore, an independent financial advisor retained by Kadimastem for the Merger, as to the valuations of NLS and Kadimastem pursuant to the Merger Agreement and as to the fairness of the Merger to Kadimastem, as more fully described below in the section entitled “ — Fairness Opinion and Valuation Reports of Moore Financial Consulting.” In addition to the above factors, the Kadimastem Board also considered several negative factors, including: •Potential issues with synergy, which need to implement and make changes in the R&D team; •Issues relating to